Inhibitory effect of 5-fluorouracil on human cytochrome P450 isoforms in human liver microsomes

European Journal of Clinical Pharmacology

Volumn 59, Issue 5-6, 2003, Pages 407-409

  Park, Ji Young ^a   Kim, Kyoung Ah ^b  

^a Gachon University College of Medicine   (South Korea)

^b Kyung Hee University   (South Korea)

Author keywords

5 Fluorouracil (5 FU); Cytochrome P450; Warfarin

Indexed keywords

CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; FLUOROURACIL; ISOPROTEIN;

ARTICLE; CATALYSIS; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; LIVER MICROSOME; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CATALYSIS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FLUOROURACIL; HUMANS; ISOENZYMES; MICROSOMES, LIVER; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 0141483127     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-003-0641-z     Document Type: Article

References (27)

1. Haskell CM (1995) Cancer treatment. WB Saunders, Los Angeles
2. Brown MC (1997) Multisite mucous membrane bleeding due to a possible interaction between warfarin and 5-fluorouracil. Pharmacotherapy 17:631-633
3. Brown MC (1999) An adverse interaction between warfarin and 5-fluorouracil: a case report and review of the literature. Chemotherapy 45:392-395
4. Aki Z, Kotiloglu G, Ozyilkan O (2000) A patient with a prolonged prothrombin time due to an adverse interaction between 5-fluorouracil and warfarin. Am J Gastroenterol 95:1093-1094
5. Kolesar JM, Johnson CL, Freeberg BL, Berlin JD, Schiller JH (1999) Warfarin-5-FU interaction - a consecutive case series. Pharmacotherapy 19:1445-1449
6. Gilbar PJ, Brodribb TR (2001) Phenytoin and fluorouracil interaction. Ann Pharmacother 35:1367-1370
7. Kaminsky LS, Zhang ZY (1997) Human P450 metabolism of warfarin. Pharmacol Ther 73:67-74
8. Shin JG, Park JY, Kim MJ, Shon JH, Yoon YR, Cha IJ, Lee SS, Oh SW, Kim SW, Flockhart DA (2002) Inhibitory effects of tricyclic antidepressants (TCAs) on human cytochrome P450 enzymes in vitro: mechanism of drug interaction between TCAs and phenytoin. Drug Metab Dispos 30:1102-1107
9. Bourrie M, Meunier V, Berger Y, Fabre G (1996) Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther 277:321-332
10. Tassaneeyakul W, Birkett DJ, Veronese ME, McManus ME, Tukey RH, Quattrochi LC, Gelboin HV, Miners JO (1993) Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J Pharmacol Exp Ther 265:401-407
11. Rettie AE, Korzekwa KR, Kunze KL, Lawrence RF, Eddy AC, Aoyama T, Gelboin HV, Gonzalez FJ, Trager WF (1992) Hydroxylation of S-warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of S-warfarin-drug interactions. Chem Res Toxicol 5:54-59
12. Wrighton SA, Stevens JC, Becker GW, VandenBranden M (1993) Isolation and characterization of human cytochrome P4502C19: correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch Biochem Biophys 306:240-245
13. Broly F, Libersa C, Lhermitte M, Bechtel P, Dupuis B (1989) Effect of quinidine on the dextromethorphan O-demethylase activity of microsomal fractions from human liver. Br J Clin Pharmacol 28:29-36
14. Harris JW, Rahman A, Kim BR, Guengerich FP, Collins JM (1994) Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res 54:4026-4035
15. Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Hartwell PS, Raisys VA, Marsh CL, McVicar JP, Barr DM, Perkins JD (1994) Use of midazolam as a human cytochrome P450 3A probe. II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. J Pharmacol Exp Ther 271:557-566
16. Sesardic D, Boobis AR, Murray BP, Murray S, Segura J, de la Torre R, Davies DS (1990) Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. Br J Clin Pharmacol 29:651-663
17. Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE, Chenery RJ (1995) Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 25:261-270
18. Ko JW, Sukhova N, Thacker D, Chen P, Flockhart DA (1997) Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos 25:853-862
19. Broly F, Libersa C, Lhermitte M, Bechtel P, Dupuis B (1989) Effect of quinidine on the dextromethorphan O-demethylase activity of microsomal fractions from human liver. Br J Clin Pharmacol 28:29-36
20. Desai PB, Duan JZ, Zhu YW, Kouzi S (1998) Human liver microsomal metabolism of paclitaxel and drug interactions. Eur J Drug Metab Pharmacokinet 23:417-424
21. Court MH, Von Moltke LL, Shader RI, Greenblatt DJ (1997) Biotransformation of chlorzoxazone by hepatic microsomes from humans and ten other mammalian species. Biopharm Drug Dispos 18:213-226
22. Zhou Q, Chan E (2002) Effect of 5-fluorouracil on the anti-coagulant activity and the pharmacokinetics of warfarin enantiomers in rats. Eur J Pharm Sci 17:73-80
23. Levy RH (1995) Cytochrome P450 isoenzymes and antiepileptic drug interactions. Epilepsia 36[Suppl 5]:S8-S15
24. Haaz MC, Rivory L, Riche C, Vernillet L, Robert J (1998) Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P450 3A and drug interactions. Cancer Res 58:468-472
25. Afsar A, Lee C, Riddick DS (1996) Modulation of the expression on constitutive rat hepatic cytochrome P450 isozymes by 5-fluorouracil. Can J Physiol Pharmacol 74:150-156
26. Stupans I, Richards DA, McClure MT (1995) Effects of 5-fluorouracil treatment on rat liver microsomal enzymes. Xenobiotica 25:1-8
27. Yoshisue K, Nagayama S, Shindo T, Kawaguchi Y (2001) Effects of 5-fluorouracil on the drug-metabolizing enzymes of the small intestine and the consequent drug interaction with nifedipine in rats. J Pharmacol Exp Ther 297:1166-1175